Steven Kanner
Chief Tech/Sci/R&D Officer at CARIBOU BIOSCIENCES, INC.
Net worth: 1 M $ as of 2024-04-29
Steven Kanner active positions
Companies | Position | Start | End |
---|---|---|---|
CARIBOU BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2017-05-31 | - |
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Director/Board Member | 2023-10-09 | - |
Independent Dir/Board Member | 2023-10-09 | - |
Career history of Steven Kanner
Former positions of Steven Kanner
Companies | Position | Start | End |
---|---|---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2013-09-18 | 2017-05-31 |
Training of Steven Kanner
University of California, Berkeley | Undergraduate Degree |
The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Statistics
International
United States | 5 |
Canada | 2 |
Operational
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
CARIBOU BIOSCIENCES, INC. | Health Technology |
Private companies | 1 |
---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Stock Market
- Insiders
- Steven Kanner
- Experience